This is risky business. Only invest what you can afford to lose.
Followers | 0 |
Posts | 1,505 |
Boards Moderated | 0 |
Alias Born | 02/27/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This really is the right phase of this play to get in, before the larger awareness manifests. Discount hunters tucked away a few more on friday
All in all, the extra volume points to the new eyes that are trained here. Starting to grab some radar. We are approaching a tipping point soon
Johns Hopkins is no slouch of a hospital
Dang!
VYCO- another trade at ASK
VYCO ask is getting hit
VYCO, another trade at ASK
VYCO Ask knocking again, 1 mm left
VYCO, Nibbling at the ASK again, one MM to go
VYCO Ask getting tapped again
Another volatile day here
6k shares traded at ASK
VYCO: 1 MM to go, FDA approves technology :
http://articles.nydailynews.com/2011-06-19/news/29696861_1_vada-vasquez-sundaresan-stray-bullet
New brain tumor technology helps man who took two bullets to the head return to normal life
BY PATRICE O'SHAUGHNESSY
DAILY NEWS STAFF WRITER
Sunday, June 19, 2011
Jesus Barrios was shot twice in the head, with one bullet passing through and leaving staple-sized fragments in his brain. He faced a future of seizures, infection and vision loss because it's too risky to remove the specks.
But Dr. Narayan Sundaresan, chief neurosurgeon at Lincoln Hospital, decided to try a new technology for brain tumors on Barrios - the first-ever such use on a gunshot victim - and was able to extract the fragments.
Two months later, the 29-year-old Barrios is returning to work as a Bronx building super and enjoying life with his wife, Krystal and son, Ethan.
"I'm great," he said. "I only have a little pain; I still have one fragment in my jaw. My vision is getting better. My boy is 6 years old
... I didn't know if I would ever see him again."
"He has an excellent prognosis," Sundaresan said.
Vycor Medical Inc., the company that makes the ViewSite Brain Access System Sundaresan used, hadn't envisioned it for this use. Some 60 hospitals nationwide have the product.
"We were somewhat surprised," said Vycor's president, Ken Coviello. "We tried to design a product for deep brain access, to reach deep targets, small tumors, hematomas.
"Bullets were never on the radar. This is the first bullet to be removed."
Coviello said the breakthrough use has wartime implications, for use at frontline hospitals to stabilize patients.
Barrios said he's glad the procedure may help soldiers on distant battlefields, as well as city shooting victims. "That's great, really great," he said.
"Unfortunately, we have many gunshot victims," said Sundaresan, who made headlines two years ago when he saved Vada Vasquez, a teenage girl hit in the head by a stray bullet.
On April 8, police responded to a Tinton Ave. building in the Bronx and found Barrios and his friend, Giovanni Rivera, both shot in the head.
Rivera died at Lincoln and Barrios was rushed into surgery.
"One bullet went from one side to the other and left fragments deep in the brain," Sundaresan said.
"I wanted to remove them because they would cause seizures and they cause tremendous problems; MRIs can't be done. The problem always has been that you have to go through normal tissue and hunt for pellets, causing trauma to the brain."
Lincoln had recently acquired the Vycor product and Sundaresan used it on Barrios. The technology looks like a speculum, a tube.
"You look through it with endoscope, it's married to a computer that guides the passage so you can see into the depths, it shows us which direction to take," the surgeon said.
One fragment in the right side was close to the sinus and another was in the left side where the visual cortex resides. He removed them both.
"We would not have attempted this without this technology," Sundaresan said. "It's very exciting."
poshaughnessy@nydailynews.com
$$VYCO: Technology is already saving lives, FDA approved:
http://articles.nydailynews.com/2011-06-19/news/29696861_1_vada-vasquez-sundaresan-stray-bullet
New brain tumor technology helps man who took two bullets to the head return to normal life
BY PATRICE O'SHAUGHNESSY
DAILY NEWS STAFF WRITER
Sunday, June 19, 2011
Jesus Barrios was shot twice in the head, with one bullet passing through and leaving staple-sized fragments in his brain. He faced a future of seizures, infection and vision loss because it's too risky to remove the specks.
But Dr. Narayan Sundaresan, chief neurosurgeon at Lincoln Hospital, decided to try a new technology for brain tumors on Barrios - the first-ever such use on a gunshot victim - and was able to extract the fragments.
Two months later, the 29-year-old Barrios is returning to work as a Bronx building super and enjoying life with his wife, Krystal and son, Ethan.
"I'm great," he said. "I only have a little pain; I still have one fragment in my jaw. My vision is getting better. My boy is 6 years old
... I didn't know if I would ever see him again."
"He has an excellent prognosis," Sundaresan said.
Vycor Medical Inc., the company that makes the ViewSite Brain Access System Sundaresan used, hadn't envisioned it for this use. Some 60 hospitals nationwide have the product.
"We were somewhat surprised," said Vycor's president, Ken Coviello. "We tried to design a product for deep brain access, to reach deep targets, small tumors, hematomas.
"Bullets were never on the radar. This is the first bullet to be removed."
Coviello said the breakthrough use has wartime implications, for use at frontline hospitals to stabilize patients.
Barrios said he's glad the procedure may help soldiers on distant battlefields, as well as city shooting victims. "That's great, really great," he said.
"Unfortunately, we have many gunshot victims," said Sundaresan, who made headlines two years ago when he saved Vada Vasquez, a teenage girl hit in the head by a stray bullet.
On April 8, police responded to a Tinton Ave. building in the Bronx and found Barrios and his friend, Giovanni Rivera, both shot in the head.
Rivera died at Lincoln and Barrios was rushed into surgery.
"One bullet went from one side to the other and left fragments deep in the brain," Sundaresan said.
"I wanted to remove them because they would cause seizures and they cause tremendous problems; MRIs can't be done. The problem always has been that you have to go through normal tissue and hunt for pellets, causing trauma to the brain."
Lincoln had recently acquired the Vycor product and Sundaresan used it on Barrios. The technology looks like a speculum, a tube.
"You look through it with endoscope, it's married to a computer that guides the passage so you can see into the depths, it shows us which direction to take," the surgeon said.
One fragment in the right side was close to the sinus and another was in the left side where the visual cortex resides. He removed them both.
"We would not have attempted this without this technology," Sundaresan said. "It's very exciting."
poshaughnessy@nydailynews.com
VYCO: one MM to go, NYdaily news article on life saving VYCO technology:
http://articles.nydailynews.com/2011-06-19/news/29696861_1_vada-vasquez-sundaresan-stray-bullet
New brain tumor technology helps man who took two bullets to the head return to normal life
BY PATRICE O'SHAUGHNESSY
DAILY NEWS STAFF WRITER
Sunday, June 19, 2011
Jesus Barrios was shot twice in the head, with one bullet passing through and leaving staple-sized fragments in his brain. He faced a future of seizures, infection and vision loss because it's too risky to remove the specks.
But Dr. Narayan Sundaresan, chief neurosurgeon at Lincoln Hospital, decided to try a new technology for brain tumors on Barrios - the first-ever such use on a gunshot victim - and was able to extract the fragments.
Two months later, the 29-year-old Barrios is returning to work as a Bronx building super and enjoying life with his wife, Krystal and son, Ethan.
"I'm great," he said. "I only have a little pain; I still have one fragment in my jaw. My vision is getting better. My boy is 6 years old
... I didn't know if I would ever see him again."
"He has an excellent prognosis," Sundaresan said.
Vycor Medical Inc., the company that makes the ViewSite Brain Access System Sundaresan used, hadn't envisioned it for this use. Some 60 hospitals nationwide have the product.
"We were somewhat surprised," said Vycor's president, Ken Coviello. "We tried to design a product for deep brain access, to reach deep targets, small tumors, hematomas.
"Bullets were never on the radar. This is the first bullet to be removed."
Coviello said the breakthrough use has wartime implications, for use at frontline hospitals to stabilize patients.
Barrios said he's glad the procedure may help soldiers on distant battlefields, as well as city shooting victims. "That's great, really great," he said.
"Unfortunately, we have many gunshot victims," said Sundaresan, who made headlines two years ago when he saved Vada Vasquez, a teenage girl hit in the head by a stray bullet.
On April 8, police responded to a Tinton Ave. building in the Bronx and found Barrios and his friend, Giovanni Rivera, both shot in the head.
Rivera died at Lincoln and Barrios was rushed into surgery.
"One bullet went from one side to the other and left fragments deep in the brain," Sundaresan said.
"I wanted to remove them because they would cause seizures and they cause tremendous problems; MRIs can't be done. The problem always has been that you have to go through normal tissue and hunt for pellets, causing trauma to the brain."
Lincoln had recently acquired the Vycor product and Sundaresan used it on Barrios. The technology looks like a speculum, a tube.
"You look through it with endoscope, it's married to a computer that guides the passage so you can see into the depths, it shows us which direction to take," the surgeon said.
One fragment in the right side was close to the sinus and another was in the left side where the visual cortex resides. He removed them both.
"We would not have attempted this without this technology," Sundaresan said. "It's very exciting."
poshaughnessy@nydailynews.com
VYCO: .02- only one MM to go, technology is already saving lives:
http://articles.nydailynews.com/2011-06-19/news/29696861_1_vada-vasquez-sundaresan-stray-bullet
New brain tumor technology helps man who took two bullets to the head return to normal life
BY PATRICE O'SHAUGHNESSY
DAILY NEWS STAFF WRITER
Sunday, June 19, 2011
Jesus Barrios was shot twice in the head, with one bullet passing through and leaving staple-sized fragments in his brain. He faced a future of seizures, infection and vision loss because it's too risky to remove the specks.
But Dr. Narayan Sundaresan, chief neurosurgeon at Lincoln Hospital, decided to try a new technology for brain tumors on Barrios - the first-ever such use on a gunshot victim - and was able to extract the fragments.
Two months later, the 29-year-old Barrios is returning to work as a Bronx building super and enjoying life with his wife, Krystal and son, Ethan.
"I'm great," he said. "I only have a little pain; I still have one fragment in my jaw. My vision is getting better. My boy is 6 years old
... I didn't know if I would ever see him again."
"He has an excellent prognosis," Sundaresan said.
Vycor Medical Inc., the company that makes the ViewSite Brain Access System Sundaresan used, hadn't envisioned it for this use. Some 60 hospitals nationwide have the product.
"We were somewhat surprised," said Vycor's president, Ken Coviello. "We tried to design a product for deep brain access, to reach deep targets, small tumors, hematomas.
"Bullets were never on the radar. This is the first bullet to be removed."
Coviello said the breakthrough use has wartime implications, for use at frontline hospitals to stabilize patients.
Barrios said he's glad the procedure may help soldiers on distant battlefields, as well as city shooting victims. "That's great, really great," he said.
"Unfortunately, we have many gunshot victims," said Sundaresan, who made headlines two years ago when he saved Vada Vasquez, a teenage girl hit in the head by a stray bullet.
On April 8, police responded to a Tinton Ave. building in the Bronx and found Barrios and his friend, Giovanni Rivera, both shot in the head.
Rivera died at Lincoln and Barrios was rushed into surgery.
"One bullet went from one side to the other and left fragments deep in the brain," Sundaresan said.
"I wanted to remove them because they would cause seizures and they cause tremendous problems; MRIs can't be done. The problem always has been that you have to go through normal tissue and hunt for pellets, causing trauma to the brain."
Lincoln had recently acquired the Vycor product and Sundaresan used it on Barrios. The technology looks like a speculum, a tube.
"You look through it with endoscope, it's married to a computer that guides the passage so you can see into the depths, it shows us which direction to take," the surgeon said.
One fragment in the right side was close to the sinus and another was in the left side where the visual cortex resides. He removed them both.
"We would not have attempted this without this technology," Sundaresan said. "It's very exciting."
poshaughnessy@nydailynews.com
VYCO: .02- only one MM to go, technology is already saving lives:
http://articles.nydailynews.com/2011-06-19/news/29696861_1_vada-vasquez-sundaresan-stray-bullet
New brain tumor technology helps man who took two bullets to the head return to normal life
BY PATRICE O'SHAUGHNESSY
DAILY NEWS STAFF WRITER
Sunday, June 19, 2011
Jesus Barrios was shot twice in the head, with one bullet passing through and leaving staple-sized fragments in his brain. He faced a future of seizures, infection and vision loss because it's too risky to remove the specks.
But Dr. Narayan Sundaresan, chief neurosurgeon at Lincoln Hospital, decided to try a new technology for brain tumors on Barrios - the first-ever such use on a gunshot victim - and was able to extract the fragments.
Two months later, the 29-year-old Barrios is returning to work as a Bronx building super and enjoying life with his wife, Krystal and son, Ethan.
"I'm great," he said. "I only have a little pain; I still have one fragment in my jaw. My vision is getting better. My boy is 6 years old
... I didn't know if I would ever see him again."
"He has an excellent prognosis," Sundaresan said.
Vycor Medical Inc., the company that makes the ViewSite Brain Access System Sundaresan used, hadn't envisioned it for this use. Some 60 hospitals nationwide have the product.
"We were somewhat surprised," said Vycor's president, Ken Coviello. "We tried to design a product for deep brain access, to reach deep targets, small tumors, hematomas.
"Bullets were never on the radar. This is the first bullet to be removed."
Coviello said the breakthrough use has wartime implications, for use at frontline hospitals to stabilize patients.
Barrios said he's glad the procedure may help soldiers on distant battlefields, as well as city shooting victims. "That's great, really great," he said.
"Unfortunately, we have many gunshot victims," said Sundaresan, who made headlines two years ago when he saved Vada Vasquez, a teenage girl hit in the head by a stray bullet.
On April 8, police responded to a Tinton Ave. building in the Bronx and found Barrios and his friend, Giovanni Rivera, both shot in the head.
Rivera died at Lincoln and Barrios was rushed into surgery.
"One bullet went from one side to the other and left fragments deep in the brain," Sundaresan said.
"I wanted to remove them because they would cause seizures and they cause tremendous problems; MRIs can't be done. The problem always has been that you have to go through normal tissue and hunt for pellets, causing trauma to the brain."
Lincoln had recently acquired the Vycor product and Sundaresan used it on Barrios. The technology looks like a speculum, a tube.
"You look through it with endoscope, it's married to a computer that guides the passage so you can see into the depths, it shows us which direction to take," the surgeon said.
One fragment in the right side was close to the sinus and another was in the left side where the visual cortex resides. He removed them both.
"We would not have attempted this without this technology," Sundaresan said. "It's very exciting."
poshaughnessy@nydailynews.com
VYCO: .02- only one MM to go, FDA approved, technology is already saving lives:
http://articles.nydailynews.com/2011-06-19/news/29696861_1_vada-vasquez-sundaresan-stray-bullet
New brain tumor technology helps man who took two bullets to the head return to normal life
BY PATRICE O'SHAUGHNESSY
DAILY NEWS STAFF WRITER
Sunday, June 19, 2011
Jesus Barrios was shot twice in the head, with one bullet passing through and leaving staple-sized fragments in his brain. He faced a future of seizures, infection and vision loss because it's too risky to remove the specks.
But Dr. Narayan Sundaresan, chief neurosurgeon at Lincoln Hospital, decided to try a new technology for brain tumors on Barrios - the first-ever such use on a gunshot victim - and was able to extract the fragments.
Two months later, the 29-year-old Barrios is returning to work as a Bronx building super and enjoying life with his wife, Krystal and son, Ethan.
"I'm great," he said. "I only have a little pain; I still have one fragment in my jaw. My vision is getting better. My boy is 6 years old
... I didn't know if I would ever see him again."
"He has an excellent prognosis," Sundaresan said.
Vycor Medical Inc., the company that makes the ViewSite Brain Access System Sundaresan used, hadn't envisioned it for this use. Some 60 hospitals nationwide have the product.
"We were somewhat surprised," said Vycor's president, Ken Coviello. "We tried to design a product for deep brain access, to reach deep targets, small tumors, hematomas.
"Bullets were never on the radar. This is the first bullet to be removed."
Coviello said the breakthrough use has wartime implications, for use at frontline hospitals to stabilize patients.
Barrios said he's glad the procedure may help soldiers on distant battlefields, as well as city shooting victims. "That's great, really great," he said.
"Unfortunately, we have many gunshot victims," said Sundaresan, who made headlines two years ago when he saved Vada Vasquez, a teenage girl hit in the head by a stray bullet.
On April 8, police responded to a Tinton Ave. building in the Bronx and found Barrios and his friend, Giovanni Rivera, both shot in the head.
Rivera died at Lincoln and Barrios was rushed into surgery.
"One bullet went from one side to the other and left fragments deep in the brain," Sundaresan said.
"I wanted to remove them because they would cause seizures and they cause tremendous problems; MRIs can't be done. The problem always has been that you have to go through normal tissue and hunt for pellets, causing trauma to the brain."
Lincoln had recently acquired the Vycor product and Sundaresan used it on Barrios. The technology looks like a speculum, a tube.
"You look through it with endoscope, it's married to a computer that guides the passage so you can see into the depths, it shows us which direction to take," the surgeon said.
One fragment in the right side was close to the sinus and another was in the left side where the visual cortex resides. He removed them both.
"We would not have attempted this without this technology," Sundaresan said. "It's very exciting."
poshaughnessy@nydailynews.com
VYCO: .02- only one MM to go, technology is already saving lives:
http://articles.nydailynews.com/2011-06-19/news/29696861_1_vada-vasquez-sundaresan-stray-bullet
New brain tumor technology helps man who took two bullets to the head return to normal life
BY PATRICE O'SHAUGHNESSY
DAILY NEWS STAFF WRITER
Sunday, June 19, 2011
Jesus Barrios was shot twice in the head, with one bullet passing through and leaving staple-sized fragments in his brain. He faced a future of seizures, infection and vision loss because it's too risky to remove the specks.
But Dr. Narayan Sundaresan, chief neurosurgeon at Lincoln Hospital, decided to try a new technology for brain tumors on Barrios - the first-ever such use on a gunshot victim - and was able to extract the fragments.
Two months later, the 29-year-old Barrios is returning to work as a Bronx building super and enjoying life with his wife, Krystal and son, Ethan.
"I'm great," he said. "I only have a little pain; I still have one fragment in my jaw. My vision is getting better. My boy is 6 years old
... I didn't know if I would ever see him again."
"He has an excellent prognosis," Sundaresan said.
Vycor Medical Inc., the company that makes the ViewSite Brain Access System Sundaresan used, hadn't envisioned it for this use. Some 60 hospitals nationwide have the product.
"We were somewhat surprised," said Vycor's president, Ken Coviello. "We tried to design a product for deep brain access, to reach deep targets, small tumors, hematomas.
"Bullets were never on the radar. This is the first bullet to be removed."
Coviello said the breakthrough use has wartime implications, for use at frontline hospitals to stabilize patients.
Barrios said he's glad the procedure may help soldiers on distant battlefields, as well as city shooting victims. "That's great, really great," he said.
"Unfortunately, we have many gunshot victims," said Sundaresan, who made headlines two years ago when he saved Vada Vasquez, a teenage girl hit in the head by a stray bullet.
On April 8, police responded to a Tinton Ave. building in the Bronx and found Barrios and his friend, Giovanni Rivera, both shot in the head.
Rivera died at Lincoln and Barrios was rushed into surgery.
"One bullet went from one side to the other and left fragments deep in the brain," Sundaresan said.
"I wanted to remove them because they would cause seizures and they cause tremendous problems; MRIs can't be done. The problem always has been that you have to go through normal tissue and hunt for pellets, causing trauma to the brain."
Lincoln had recently acquired the Vycor product and Sundaresan used it on Barrios. The technology looks like a speculum, a tube.
"You look through it with endoscope, it's married to a computer that guides the passage so you can see into the depths, it shows us which direction to take," the surgeon said.
One fragment in the right side was close to the sinus and another was in the left side where the visual cortex resides. He removed them both.
"We would not have attempted this without this technology," Sundaresan said. "It's very exciting."
poshaughnessy@nydailynews.com
VYCO: 1 mm till .0215, Piper Jaffery estimated intellectual property at 50mm alone for NovaVision division DD will rock your world: http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO: 1 mm till .0215, Piper Jaffery estimated intellectual property at 50mm alone for NovaVision division
~VYCO: .019 x .02, 1 mm at Ask, DD is worth looking at:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
~VYCO: .019 x .02, 1 mm at Ask, great volume this week
~VYCO: .019 x .02, 1 mm at Ask, snap up some discount
And that's the NYDaily News, *NOT* investor relations or some PR
My sentiments exactly, the deeper you dig here, the more confidence you feel. With exclusive FDA approval, patented technology, worldwide distributors and rising revenues, the risk is essentially out of the deal. There are tickers trading on the NASDAQ right now with market Caps many multiples of VYCO who don't have any of that. If all VYCO had was the intellectual property this would still be undervalued
Some twit's been selling on NITE alot of this week, but there's been no lack of people wanting to get in at nice discount
Just the sign to get some more at discount
10% of the players make 90% of the money. Wanna make more ROI? Just follow the smart money ;-D You only have to look at the boardmarks here on the IHUB board to see that this is still relatively undiscoverd Gem. Its the big swinging sticks who drop 10k, 15k at a time and let it ride, trusting their hard won instincts who have have been creating all the activity here lately, not day traders who drop $500 and bit their nails looking to jump out when they've made 25%
Yes, all the recent volume has been fairly news independent. Just savvy players waking up to huge opportunity and getting in on word of mouth. Can you imagine what will happen when the next piece of news comes out with all these eyes on it? Lot of things, *real* things could possibly break here soon, i.e. the European deals, China orders, Indian hospitals, etc.
VYCO is different kind of play. The pace is not your typical penny pop and drop artificially inflated by the latest hyped up PR written with more conditionals than a Hollywood prenup. The rise in activity we've seen over the last several weeks is mostly buying by savvy, deep pocket investors front loading big time based on their own deep digging DD. Those types of investors trust their own judgement ( and why shouldn't they, its made them a fortune). They have made their bucks getting in *before* the mad rush. They aren't afraid to let their bets ride for a couple weeks while Joe Public hits the snooze button one last time. I'm not white knuckling this, biting my nails at every fluctuation like I normally do with your average puff of smoke penny play. Undervalued is undervalued. I have a confident mind of where this is headed.
Seems like the piker on NITE has been cleared out. Volume a little slow so far for a friday, relatively speaking.
• The Company Should Enter Hyper-growth During the Next Two to Three Years
Vycor's ViewSite is already making good inroads into the relatively small neurosurgery
market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early
2013. However, we are most excited about the long-term potential of the NovaVision
subsidiary, as its products have no real competition and address a global market that could be
up to $20B in size. Although NovaVision's products could require several years to achieve
market penetration of even 5%, this would still equate to a huge win for a company of this size.
Both NovaVision and ViewSite have strong patent protection and backing from the scientific
community, and both are FDA 510(k) cleared for sale in the United States.
• We Believe an Investment in Vycor is Somewhat Risky but Has Exceptional Potential
Based on solid near-term growth prospects and extreme upside in potential in 2013 and
beyond, we are initiating coverage of Vycor with a Strong Buy rating and a target price range
of $0.05 per share. Assuming the Company executes on its plan over the next 12-18 months,
we believe its current valuation multiple of just 4.2x our 2013 revenue forecast is far too low,
and believe a multiple in the 12x to 15x range is more appropriate. Furthermore, we see upside
to our estimates if NovaVision is able to achieve market penetration more quickly than we
foresee.
• ViewSite Helps Neurosurgeons Address "Inoperable" Cases and Improves Outcomes
The transparent ViewSite Brain Access System (VBAS) dramatically reduces the damage
caused by "retractors" that surgeons now use to reach sub-surface areas of the brain. It also
provides these surgeons with superior visibility during surgical procedures. The net effect of
this is improved clinical outcomes, shorter surgeries, and shorter recovery times; in some cases
this product's superior attributes have allowed brain surgeons to successfully perform surgeries
that would have otherwise been considered inoperable. The VBAS is protected by a strong
patent portfolio, and we believe its clinical superiority and cost savings will lead it to become
the de facto standard in surgical devices for neurosurgery over the next few years.
• $1B+ Market Opportunity - First Real Treatment for Stroke-Related Vision Loss
Vycor's NovaVision helps victims of stroke and traumatic-brain injury permanently regain a
key portion of lost vision-field. This is the first treatment for what has been considered a
permanent and irreversible condition, and is backed by a strong scientific team, 15 years of
research and 20 clinical studies. It is FDA 510(k) cleared, has a strong patent portfolio, and
addresses a very large market in the United States, Europe, and around the world. Although
we believe it will take NovaVision several years to penetrate a big percentage of this market,
its multi-billion dollar size makes this product line a potential blockbuster for Vycor.
Morning VYCO friends. Extremely curious to see what today holds. Hoping that NITE is finally cleared out. Looking to see that accumulation trend continue
Hi Silky, Thanks for the invite. $$VYCO is a very interesting play that I'm going long on. Not the average promo based pop and drop. There's a grass roots movement of investors that believe in the company and technology and are buying, holding and spreading the word. A few reasons why:
-the NovaVision technology is proven to restore stroke related vision loss, a type of blindness considered incurable by medical science for the last hundred years
-stroke victims have had such large improvements in their vision that they can do things like drive cars again
- the only company with this technology to be FDA approved
- very strong patent suite means no competition
-their Viewsite technology enables previously impossible neurosurgeries to be performed successfully, i.e. bullet shrapnel removed without damaging surrounding brain tissue
-also patented and FDA approved
- VYCO has already penetrated a $10BB market, 3000 procedures performed, distributing to hundreds of hospitals, revenues doubled in last quarter
-Harvard Med School profs on the board
-check out this video: http://player.vimeo.com/video/39903199
Bouncing today